BiotechTube
Home/Pipeline/XAB05/XAB06

XAB05/XAB06

Bacterial Infections

PreclinicalActive

Key Facts

Indication
Bacterial Infections
Phase
Preclinical
Status
Active
Company
Xenothera

About Xenothera

Xenothera is a clinical-stage biotech with a unique focus on engineering polyclonal antibodies. Its core technology, glyco-humanization (GH), removes non-human sugar antigens from antibodies derived from animals, aiming to create multispecific, low-immunogenicity therapies. The company has built an active pipeline targeting solid tumors, T-cell lymphomas, and infectious diseases, with its lead oncology candidate, XON7, already in clinical trials since 2023. Backed by a seasoned leadership team and strategic collaborations, Xenothera is positioning itself as an innovator in complex antibody therapeutics.

View full company profile

Therapeutic Areas

OncologyInfectious DiseasesImmunology

Other Bacterial Infections Drugs

DrugCompanyPhase
Azithromycin Preparationscspc-pharmaceuticalCommercial
Penem Preparationscspc-pharmaceuticalCommercial
Various Penicillin/Cephalosporin Productscspc-pharmaceuticalCommercial
Nemonoxacin Malate CapsulesZhejiang MedicineCommercial
Generic Portfolio Expansion - Anti-infectivesAlkaloid AD SkopjeRegulatory Submission
Clindamycin Phosphate InjectionViwitCommercial
Levofloxacin Hydrochloride InjectionViwitCommercial
Meropenem-VaborbactamSciClone PharmaceuticalsCommercial (in China)
Vibativ® (telavancin)Cleo Life SciencesApproved
Penicillin V APIBiotikaCommercial
Sterile Injectable Antibiotics PortfolioSteripharmaApproved
Oral AntibioticDawah PharmaceuticalsANDA Filed/Pre-approval